Yetunde F. Fakile
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yetunde F. Fakile has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
Ellen N Kersh
Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
3 shared publicationsJames Mitchell
Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia
3 shared publications- Abigail Norris Turner
Division of Epidemiology, The Ohio State University College of Public Health, Columbus, OH, USA
2 shared publications - Alex de Voux
Division of Epidemiology and Biostatistics, School of Public Health, University of Cape Town, Cape Town, South Africa
2 shared publications Andre Hopkins
Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
2 shared publications- Andrew B. Trotter
Division of Infectious Disease, Department of Medicine University of Illinois Chicago College of Medicine Chicago Illinois USA
2 shared publications
Latest Publications
- 4 November 2022
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 11 (11) , e40095
Factors Associated With Syphilis Transmission and Acquisition Among Men Who Have Sex With Men: Protocol for a Multisite Egocentric Network Study
Background: In the United States, the rates of primary and secondary syphilis have increased more rapidly among men who have sex with men (MSM) than among any other subpopulation. Rising syphilis rates among MSM reflect changes in both individual behaviors and the role of sexual networks (eg, persons linked directly or indirectly by sexual contact) in the spread of the infection. Decades of research examined how sexual networks influence sexually transmitted infections (STIs) among MSM; however, few longitudinal data sources focusing on syphilis have collected network characteristics. The Centers for Disease Control and Prevention, in collaboration with 3 sites, enrolled a prospective cohort of MSM in 3 US cities to longitudinally study sexual behaviors and STIs, including HIV, for up to 24 months. Objective: The Network Epidemiology of Syphilis Transmission (NEST) study aimed to collect data on the factors related to syphilis transmission and acquisition among MSM. Methods: The NEST study was a prospective cohort study that enrolled 748 MSM in Baltimore, Maryland; Chicago, Illinois; and Columbus, Ohio. NEST recruitment used a combination of convenience sampling, venue-based recruitment, and respondent-driven sampling approaches. At quarterly visits, participants completed a behavioral questionnaire and were tested for syphilis, HIV, gonorrhea, and chlamydia. The participants also provided a list of their sexual partners and described their 3 most recent partners in greater detail. Results: The NEST participants were enrolled in the study from July 2018 to December 2021. At baseline, the mean age of the participants was 31.5 (SD 9.1) years. More than half (396/727. 54.5%) of the participants were non-Hispanic Black, 29.8% (217/727) were non-Hispanic White, and 8.8% (64/727) were Hispanic or Latino. Multiple recruitment strategies across the 3 study locations, including respondent-driven sampling, clinic referrals, flyers, and social media advertisements, strengthened NEST participation. Upon the completion of follow-up visits in March 2022, the mean number of visits per participant was 5.1 (SD 3.2; range 1-9) in Baltimore, 2.2 (SD 1.6; range 1-8) in Chicago, and 7.2 (SD 2.9; range 1-9) in Columbus. Using a community-based participatory research approach, site-specific staff were able to draw upon collaborations with local communities to address stigma concerning STIs, particularly syphilis, among potential NEST participants. Community-led efforts also provided a forum for staff to describe the NEST study objectives and plans for research dissemination to the target audience. Strategies to bolster data collection during the COVID-19 pandemic included telehealth visits (all sites) and adaptation to self-collection of STI specimens (Baltimore only). Conclusions: Data from NEST will be used to address important questions regarding individual and partnership-based sexual risk behaviors among MSM, with the goal of informing interventions to prevent syphilis in high-burden areas. International Registered Report Identifier (IRRID): RR1-10.2196/40095
- 4 November 2022
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 11 (11) , e40095
Factors Associated With Syphilis Transmission and Acquisition Among Men Who Have Sex With Men: Protocol for a Multisite Egocentric Network Study
Background: In the United States, the rates of primary and secondary syphilis have increased more rapidly among men who have sex with men (MSM) than among any other subpopulation. Rising syphilis rates among MSM reflect changes in both individual behaviors and the role of sexual networks (eg, persons linked directly or indirectly by sexual contact) in the spread of the infection. Decades of research examined how sexual networks influence sexually transmitted infections (STIs) among MSM; however, few longitudinal data sources focusing on syphilis have collected network characteristics. The Centers for Disease Control and Prevention, in collaboration with 3 sites, enrolled a prospective cohort of MSM in 3 US cities to longitudinally study sexual behaviors and STIs, including HIV, for up to 24 months. Objective: The Network Epidemiology of Syphilis Transmission (NEST) study aimed to collect data on the factors related to syphilis transmission and acquisition among MSM. Methods: The NEST study was a prospective cohort study that enrolled 748 MSM in Baltimore, Maryland; Chicago, Illinois; and Columbus, Ohio. NEST recruitment used a combination of convenience sampling, venue-based recruitment, and respondent-driven sampling approaches. At quarterly visits, participants completed a behavioral questionnaire and were tested for syphilis, HIV, gonorrhea, and chlamydia. The participants also provided a list of their sexual partners and described their 3 most recent partners in greater detail. Results: The NEST participants were enrolled in the study from July 2018 to December 2021. At baseline, the mean age of the participants was 31.5 (SD 9.1) years. More than half (396/727. 54.5%) of the participants were non-Hispanic Black, 29.8% (217/727) were non-Hispanic White, and 8.8% (64/727) were Hispanic or Latino. Multiple recruitment strategies across the 3 study locations, including respondent-driven sampling, clinic referrals, flyers, and social media advertisements, strengthened NEST participation. Upon the completion of follow-up visits in March 2022, the mean number of visits per participant was 5.1 (SD 3.2; range 1-9) in Baltimore, 2.2 (SD 1.6; range 1-8) in Chicago, and 7.2 (SD 2.9; range 1-9) in Columbus. Using a community-based participatory research approach, site-specific staff were able to draw upon collaborations with local communities to address stigma concerning STIs, particularly syphilis, among potential NEST participants. Community-led efforts also provided a forum for staff to describe the NEST study objectives and plans for research dissemination to the target audience. Strategies to bolster data collection during the COVID-19 pandemic included telehealth visits (all sites) and adaptation to self-collection of STI specimens (Baltimore only). Conclusions: Data from NEST will be used to address important questions regarding individual and partnership-based sexual risk behaviors among MSM, with the goal of informing interventions to prevent syphilis in high-burden areas. International Registered Report Identifier (IRRID): RR1-10.2196/40095
- Open Access
- 6 June 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Factors Associated with Syphilis Transmission and Acquisition Among Men Who Have Sex with Men (MSM) in 3 U.S Cities: Protocol for the Network Epidemiology of Syphilis Transmission Study (NEST) (Preprint)
BACKGROUND In the United States, primary and secondary syphilis rates have increased more rapidly among men who have sex with men (MSM) than any other subpopulation. Rising syphilis rates among MSM reflect changes in both individual behaviors and the role of sexual networks (e.g., persons linked directly or indirectly by sexual contact) in infection spread. Decades of research examined how sexual networks influence sexually transmitted infections (STIs) among MSM; however, few longitudinal data sources focused on syphilis have collected network characteristics. The Centers for Disease Control and Prevention, in collaboration with three sites, enrolled a prospective cohort of MSM in three U.S. cities to longitudinally study sexual behaviors and STIs, including HIV, for up to 24 months. OBJECTIVE The Network Epidemiology of Syphilis Transmission Study (NEST) collected data on factors related to syphilis transmission and acquisition among MSM. METHODS The NEST study was a prospective cohort study that enrolled 748 MSM in Baltimore, MD, Chicago, IL, and Columbus, OH. NEST recruitment employed a combination of convenience sampling, venue-based recruitment, and respondent-driven sampling approaches. At quarterly visits, participants completed a behavioral questionnaire and tested for syphilis, HIV, gonorrhea and chlamydia. Participants also provided a list of their sexual partners and described their three most recent partners in greater detail. RESULTS NEST participants enrolled in the study from July 2018 to December 2021. At baseline, the mean age of participants was 31.5 years (standard deviation (SD): 9.1). Over half of participants were non-Hispanic Black (54.4%), 29.8% were non-Hispanic White, and 8.8% were Hispanic or Latino. Multiple recruitment strategies across the three study locations, including respondent-driven sampling, clinic referrals, flyers and social media advertisements, strengthened NEST participation. Upon completion of follow-up visits in March 2022, the mean number of visits completed was 5.1 (SD: 3.2; range = 1–9) in Baltimore, 2.2 in Chicago (SD: 1.6, range 1–8), and 7.2 (SD: 2.9; range = 1–9) in Columbus. Using a community-based participatory research approach, site-specific staff were able to draw upon collaborations with local communities to address stigma concerning STIs, particularly syphilis, among potential NEST participants. Community-led efforts also provided a forum for staff to describe NEST study objectives and plans for research dissemination to the target audience. Strategies to bolster data collection during COVID-19 included telehealth visits (all sites) and adaptation to STI specimen self-collection (Baltimore only). CONCLUSIONS Data from NEST will be used to address important questions regarding individual and partnership-based sexual risk behaviors among MSM, with the goal of informing interventions to prevent syphilis in high burden areas.
- 6 June 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessFactors Associated with Syphilis Transmission and Acquisition Among Men Who Have Sex with Men (MSM) in 3 U.S Cities: Protocol for the Network Epidemiology of Syphilis Transmission Study (NEST) (Preprint)
BACKGROUND In the United States, primary and secondary syphilis rates have increased more rapidly among men who have sex with men (MSM) than any other subpopulation. Rising syphilis rates among MSM reflect changes in both individual behaviors and the role of sexual networks (e.g., persons linked directly or indirectly by sexual contact) in infection spread. Decades of research examined how sexual networks influence sexually transmitted infections (STIs) among MSM; however, few longitudinal data sources focused on syphilis have collected network characteristics. The Centers for Disease Control and Prevention, in collaboration with three sites, enrolled a prospective cohort of MSM in three U.S. cities to longitudinally study sexual behaviors and STIs, including HIV, for up to 24 months. OBJECTIVE The Network Epidemiology of Syphilis Transmission Study (NEST) collected data on factors related to syphilis transmission and acquisition among MSM. METHODS The NEST study was a prospective cohort study that enrolled 748 MSM in Baltimore, MD, Chicago, IL, and Columbus, OH. NEST recruitment employed a combination of convenience sampling, venue-based recruitment, and respondent-driven sampling approaches. At quarterly visits, participants completed a behavioral questionnaire and tested for syphilis, HIV, gonorrhea and chlamydia. Participants also provided a list of their sexual partners and described their three most recent partners in greater detail. RESULTS NEST participants enrolled in the study from July 2018 to December 2021. At baseline, the mean age of participants was 31.5 years (standard deviation (SD): 9.1). Over half of participants were non-Hispanic Black (54.4%), 29.8% were non-Hispanic White, and 8.8% were Hispanic or Latino. Multiple recruitment strategies across the three study locations, including respondent-driven sampling, clinic referrals, flyers and social media advertisements, strengthened NEST participation. Upon completion of follow-up visits in March 2022, the mean number of visits completed was 5.1 (SD: 3.2; range = 1–9) in Baltimore, 2.2 in Chicago (SD: 1.6, range 1–8), and 7.2 (SD: 2.9; range = 1–9) in Columbus. Using a community-based participatory research approach, site-specific staff were able to draw upon collaborations with local communities to address stigma concerning STIs, particularly syphilis, among potential NEST participants. Community-led efforts also provided a forum for staff to describe NEST study objectives and plans for research dissemination to the target audience. Strategies to bolster data collection during COVID-19 included telehealth visits (all sites) and adaptation to STI specimen self-collection (Baltimore only). CONCLUSIONS Data from NEST will be used to address important questions regarding individual and partnership-based sexual risk behaviors among MSM, with the goal of informing interventions to prevent syphilis in high burden areas.
- Open Access
- 1 October 2018
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 56 (10)
Laboratory Evaluation of a Commercially Available Rapid Syphilis Test
Serological diagnosis of syphilis depends on assays that detect treponemal and nontreponemal antibodies. Laboratory certification and trained personnel are needed to perform most of these tests, while high costs and long turnaround time can hinder treatment initiation or linkage to care. A rapid treponemal syphilis test (RST) that is simple to perform, accessible, and inexpensive would be ideal. The Syphilis Health Check (SHC) assay is the only Food and Drug Administration (FDA)-cleared and Clinical Laboratory Improvement Amendments (CLIA)-waived RST in the United States. In this study, 1,406 archived human serum samples were tested using SHC and traditional treponemal and nontreponemal assays. Rapid test results were compared with treponemal data alone and with a laboratory test panel consensus defined as being reactive by both treponemal and nontreponemal assays for a given specimen, or nonreactive by both types of assays. The sensitivity and specificity of the SHC assay compared with treponemal tests alone were 88.7% (95% confidence interval [CI], 86.2 to 90.0%) and 93.1% (95% CI, 90.0 to 94.9%), respectively, while comparison with the laboratory test panel consensus showed 95.7% (95% CI, 93.6 to 97.2%) sensitivity and 93.2% (95% CI, 91.0 to 95.1%) specificity. The data were further stratified based on age, sex, pregnancy, and HIV status. The sensitivity and specificity of the SHC assay ranged from 66.7% (95% CI, 46.0 to 83.5%) to 91.7% (95% CI, 87.7 to 94.7%) and 88% (95% CI, 68.8 to 97.5%) to 100% (95% CI, 47.8 to 100%), respectively, across groups compared to traditional treponemal assays, generally increasing for all groups except the HIV-positive (HIV+) population when factoring in the laboratory test panel consensus. These data contribute to current knowledge of the SHC assay performance for distinct populations and may guide use in various settings.
- 1 October 2018
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 56 (10)
Open AccessLaboratory Evaluation of a Commercially Available Rapid Syphilis Test
Serological diagnosis of syphilis depends on assays that detect treponemal and nontreponemal antibodies. Laboratory certification and trained personnel are needed to perform most of these tests, while high costs and long turnaround time can hinder treatment initiation or linkage to care. A rapid treponemal syphilis test (RST) that is simple to perform, accessible, and inexpensive would be ideal. The Syphilis Health Check (SHC) assay is the only Food and Drug Administration (FDA)-cleared and Clinical Laboratory Improvement Amendments (CLIA)-waived RST in the United States. In this study, 1,406 archived human serum samples were tested using SHC and traditional treponemal and nontreponemal assays. Rapid test results were compared with treponemal data alone and with a laboratory test panel consensus defined as being reactive by both treponemal and nontreponemal assays for a given specimen, or nonreactive by both types of assays. The sensitivity and specificity of the SHC assay compared with treponemal tests alone were 88.7% (95% confidence interval [CI], 86.2 to 90.0%) and 93.1% (95% CI, 90.0 to 94.9%), respectively, while comparison with the laboratory test panel consensus showed 95.7% (95% CI, 93.6 to 97.2%) sensitivity and 93.2% (95% CI, 91.0 to 95.1%) specificity. The data were further stratified based on age, sex, pregnancy, and HIV status. The sensitivity and specificity of the SHC assay ranged from 66.7% (95% CI, 46.0 to 83.5%) to 91.7% (95% CI, 87.7 to 94.7%) and 88% (95% CI, 68.8 to 97.5%) to 100% (95% CI, 47.8 to 100%), respectively, across groups compared to traditional treponemal assays, generally increasing for all groups except the HIV-positive (HIV+) population when factoring in the laboratory test panel consensus. These data contribute to current knowledge of the SHC assay performance for distinct populations and may guide use in various settings.
- 1 September 2018
- Published by Elsevier in Journal of Clinical Virology
- Vol. 106, 11-12
Evaluation of a rapid point-of-care HIV screening program in an emergency department setting in Detroit, Michigan
- 1 September 2018
- Published by Elsevier in Journal of Clinical Virology
- Vol. 106, 11-12
Evaluation of a rapid point-of-care HIV screening program in an emergency department setting in Detroit, Michigan
- 1 January 2018
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 56 (1) , e01165-17
Correlation of Treponemal Immunoassay Signal Strength Values with Reactivity of Confirmatory Treponemal Testing
Automated treponemal immunoassays are used for syphilis screening with the reverse-sequence algorithm; discordant results (e.g., enzyme immunoassay [EIA] reactive and reactive plasma reagin [RPR] nonreactive) are resolved with a second treponemal test. We conducted a study to determine automated immunoassay signal strength values consistently correlating with reactive confirmatory treponemal testing. We conducted a cross-sectional analysis of four automated immunoassays (BioPlex 2200 microbead immunoassay [MBIA], Liaison chemiluminescence immunoassay [CIA], Advia-Centaur CIA, and Trep-Sure EIA) and three manual assays ( Treponema pallidum particle agglutination [TP-PA], fluorescent treponemal antibody absorption [FTA-ABS] test, and Inno-LIA line immunoassay). We compared signal strength values of automated immunoassays and positive and negative agreement. Among 1,995 specimens, 908 (45.5%) were true positives (≥4/7 tests reactive) and 1,087 (54.5%) were true negatives (≥4/7 tests nonreactive). Positive agreement ranged from 86.1% (83.7 to 88.2%) for FTA-ABS to 99.7% (99.0 to 99.9%) for Advia-Centaur CIA; negative agreement ranged from 86.3% (84.1 to 88.2%) for Trep-Sure EIA to 100% for TP-PA (99.6 to 100%). Increasing signal strength values correlated with increasing reactivity of confirmatory testing ( P < 0.0001 for all automated immunoassays by Cochran-Armitage test for trend). All automated immunoassays had signal strength cutoffs corresponding to ≥4/7 reactive treponemal tests. BioPlex MBIA and Liaison CIA had signal strength cutoffs correlating with ≥99% and 100% TP-PA reactivity, respectively. The Advia-Centaur CIA and Trep-Sure EIA had signal strength cutoffs correlating with at least 95% TP-PA reactivity. All automated immunoassays had signal strength cutoffs correlating with at least 95% FTA-ABS reactivity. Assuming that a 95% level of confirmation is adequate, these signal strength values can be used in lieu of confirmatory testing with TP-PA and FTA-ABS.
- 1 January 2018
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 56 (1) , e01165-17
Correlation of Treponemal Immunoassay Signal Strength Values with Reactivity of Confirmatory Treponemal Testing
Automated treponemal immunoassays are used for syphilis screening with the reverse-sequence algorithm; discordant results (e.g., enzyme immunoassay [EIA] reactive and reactive plasma reagin [RPR] nonreactive) are resolved with a second treponemal test. We conducted a study to determine automated immunoassay signal strength values consistently correlating with reactive confirmatory treponemal testing. We conducted a cross-sectional analysis of four automated immunoassays (BioPlex 2200 microbead immunoassay [MBIA], Liaison chemiluminescence immunoassay [CIA], Advia-Centaur CIA, and Trep-Sure EIA) and three manual assays ( Treponema pallidum particle agglutination [TP-PA], fluorescent treponemal antibody absorption [FTA-ABS] test, and Inno-LIA line immunoassay). We compared signal strength values of automated immunoassays and positive and negative agreement. Among 1,995 specimens, 908 (45.5%) were true positives (≥4/7 tests reactive) and 1,087 (54.5%) were true negatives (≥4/7 tests nonreactive). Positive agreement ranged from 86.1% (83.7 to 88.2%) for FTA-ABS to 99.7% (99.0 to 99.9%) for Advia-Centaur CIA; negative agreement ranged from 86.3% (84.1 to 88.2%) for Trep-Sure EIA to 100% for TP-PA (99.6 to 100%). Increasing signal strength values correlated with increasing reactivity of confirmatory testing ( P < 0.0001 for all automated immunoassays by Cochran-Armitage test for trend). All automated immunoassays had signal strength cutoffs corresponding to ≥4/7 reactive treponemal tests. BioPlex MBIA and Liaison CIA had signal strength cutoffs correlating with ≥99% and 100% TP-PA reactivity, respectively. The Advia-Centaur CIA and Trep-Sure EIA had signal strength cutoffs correlating with at least 95% TP-PA reactivity. All automated immunoassays had signal strength cutoffs correlating with at least 95% FTA-ABS reactivity. Assuming that a 95% level of confirmation is adequate, these signal strength values can be used in lieu of confirmatory testing with TP-PA and FTA-ABS.
- Open Access
- 22 December 2017
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 217 (7) , 1139-1144
A Nonhuman Primate Model for Rectally Transmitted Syphilis
Among men who have sex with men (MSM), those with a diagnosis of syphilis or other rectal sexually transmitted infections (STIs) are at a higher risk for human immunodeficiency virus acquisition, which is concerning given the large increase in recently reported syphilis cases in the United States. We have developed the first nonhuman primate model for rectally transmitted syphilis by exposing simian/human immunodeficiency virus–infected and naive rhesus macaques to Treponema pallidum in the rectum. All animals showed mucosal lesions, systemic dissemination, and seroconversion (treponemal antibodies). This model would be valuable for studying the manifestations of and interventions for T. pallidum infection, with and without human immunodeficiency virus coinfection.
- 22 December 2017
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 217 (7) , 1139-1144
Open AccessA Nonhuman Primate Model for Rectally Transmitted Syphilis
Among men who have sex with men (MSM), those with a diagnosis of syphilis or other rectal sexually transmitted infections (STIs) are at a higher risk for human immunodeficiency virus acquisition, which is concerning given the large increase in recently reported syphilis cases in the United States. We have developed the first nonhuman primate model for rectally transmitted syphilis by exposing simian/human immunodeficiency virus–infected and naive rhesus macaques to Treponema pallidum in the rectum. All animals showed mucosal lesions, systemic dissemination, and seroconversion (treponemal antibodies). This model would be valuable for studying the manifestations of and interventions for T. pallidum infection, with and without human immunodeficiency virus coinfection.
- Open Access
- 8 July 2017
- Published by BMJ
- Vol. 93, A60
P1.42 A new magnetic particle-based agglutination assay for anti-cardiolipin antibody detection in syphilis
Introduction A magnetic particle based assay was developed for the detection of nontreponemal anti-cardiolipin antibodies in sera of suspected syphilis cases. The presence of this group of antibodies in combination with a reactive treponemal test indicates active syphilis. In this study, we aimed to overcome technical difficulties with attaching cardiolipin to solid support. The newly developed assay potentially offers advantages of better result interpretation, accuracy, and minimum equipment need compared to traditional nontreponemal tests in diagnosing syphilis. Methods To develop the nontreponemal magnetic agglutination assay (NT-MAA), cardiolipin antigen was modified first through a chemical oxidation process. The oxidised antigen was later covalently linked to magnetic particles. To test the beads, serum samples were mixed with cardiolipin-magnetic particle complex, and incubated in round bottom well microplates. The test was interpreted as reactive when agglutination was observed. Non-reactive sample demonstrated a “button” in the centre of a microwell. The NT-MAA was evaluated using a panel of previously characterised human sera (n=80) and results were compared to rapid plasma reagin (RPR, ASI) and Treponema pallidum particle agglutination tests (TP-PA, Fujirebio). A true positive sample was defined as being reactive for both RPR and TP-PA, while a true negative as both RPR and TP-PA non-reactive. Results Out of 80 sera tested, 48 were found true positive and 32 true negative with the reference tests. In comparison, the NT-MAA, demonstrated a sensitivity and specificity of 100% and 96.8%, respectively. Conclusion Magnetic particle-based assays offer high flexibility because they work with different assay formats. This exploratory study, describes technical advances for development of nontreponemal test (NT-MAA), and also demonstrated an encouraging performance with the studied samples. Additional evaluation with syphilis samples from defined clinical stages of syphilis will help further validate test performance.
- 8 July 2017
- Published by BMJ
- Vol. 93, A60
Open AccessP1.42 A new magnetic particle-based agglutination assay for anti-cardiolipin antibody detection in syphilis
Introduction A magnetic particle based assay was developed for the detection of nontreponemal anti-cardiolipin antibodies in sera of suspected syphilis cases. The presence of this group of antibodies in combination with a reactive treponemal test indicates active syphilis. In this study, we aimed to overcome technical difficulties with attaching cardiolipin to solid support. The newly developed assay potentially offers advantages of better result interpretation, accuracy, and minimum equipment need compared to traditional nontreponemal tests in diagnosing syphilis. Methods To develop the nontreponemal magnetic agglutination assay (NT-MAA), cardiolipin antigen was modified first through a chemical oxidation process. The oxidised antigen was later covalently linked to magnetic particles. To test the beads, serum samples were mixed with cardiolipin-magnetic particle complex, and incubated in round bottom well microplates. The test was interpreted as reactive when agglutination was observed. Non-reactive sample demonstrated a “button” in the centre of a microwell. The NT-MAA was evaluated using a panel of previously characterised human sera (n=80) and results were compared to rapid plasma reagin (RPR, ASI) and Treponema pallidum particle agglutination tests (TP-PA, Fujirebio). A true positive sample was defined as being reactive for both RPR and TP-PA, while a true negative as both RPR and TP-PA non-reactive. Results Out of 80 sera tested, 48 were found true positive and 32 true negative with the reference tests. In comparison, the NT-MAA, demonstrated a sensitivity and specificity of 100% and 96.8%, respectively. Conclusion Magnetic particle-based assays offer high flexibility because they work with different assay formats. This exploratory study, describes technical advances for development of nontreponemal test (NT-MAA), and also demonstrated an encouraging performance with the studied samples. Additional evaluation with syphilis samples from defined clinical stages of syphilis will help further validate test performance.
- 8 July 2017
- Published by BMJ
- Vol. 93, A78
P2.21 Feasibility study for the development of a rapid lateral flow point of care test for congenital syphilis
Introduction The World Health Organisation (WHO) estimates there are 7 13 600 to 1,575,000 cases of congenital syphilis worldwide annually. Congenital syphilis can lead to several health conditions at birth. Currently there is no rapid point of care test available for its diagnosis.Here we introduce a novel rapid point of care test for congenital syphilis. The objective of this test includes the ability to test whole blood or serum taken from the infant or cord blood while blocking the mother’s IgG antibodies. Methods Thirty-four (34) syphilis positive and negative gestational serum samples and five (5) positive congenital syphilis samples, were obtained from University of Connecticut Health Centre. Twenty-two (22) samples were RPR reactive. Chembio DPP Syphilis IgG and IgM test devices were obtained from the manufacturer. The required number of IgG and IgM devices were modified at the CDC to include an IgG blocker in the device to produce four different assay devices used for this study. Each serum sample was tested in the four separate devices. Results were reported based on the patterns observed in the assay windows. Results All (17/17) the RPR positive gestational samples were positive (100%),and 5 of 5 congenital positive samples were positive (100%) using the IgM device with IgG blocking agent. Only 5/17 of gestational samples (29.4%) and 1/5 congenital samples (20%) were positive using the IgM device without IgG blocking agent. For the IgG device with the IgG blocking agent all samples were negative. The IgG device without the blocking reagent resulted in the detection of 19/22 (86.4%) of the RPR positive samples. With the exception of one sample all negative samples were negative by all 4 test devices. Conclusion Only a limited number of positive and negative gestational and congenital syphilis samples were evaluated in this study, due to the short supply of such rare samples. It is apparent from this limited data that by blocking the mother’s IgG an increase in sensitivity can be achieved. More in depth studies are necessary in order to prove the concept.
- 8 July 2017
- Published by BMJ
- Vol. 93, A78
P2.21 Feasibility study for the development of a rapid lateral flow point of care test for congenital syphilis
Introduction The World Health Organisation (WHO) estimates there are 7 13 600 to 1,575,000 cases of congenital syphilis worldwide annually. Congenital syphilis can lead to several health conditions at birth. Currently there is no rapid point of care test available for its diagnosis.Here we introduce a novel rapid point of care test for congenital syphilis. The objective of this test includes the ability to test whole blood or serum taken from the infant or cord blood while blocking the mother’s IgG antibodies. Methods Thirty-four (34) syphilis positive and negative gestational serum samples and five (5) positive congenital syphilis samples, were obtained from University of Connecticut Health Centre. Twenty-two (22) samples were RPR reactive. Chembio DPP Syphilis IgG and IgM test devices were obtained from the manufacturer. The required number of IgG and IgM devices were modified at the CDC to include an IgG blocker in the device to produce four different assay devices used for this study. Each serum sample was tested in the four separate devices. Results were reported based on the patterns observed in the assay windows. Results All (17/17) the RPR positive gestational samples were positive (100%),and 5 of 5 congenital positive samples were positive (100%) using the IgM device with IgG blocking agent. Only 5/17 of gestational samples (29.4%) and 1/5 congenital samples (20%) were positive using the IgM device without IgG blocking agent. For the IgG device with the IgG blocking agent all samples were negative. The IgG device without the blocking reagent resulted in the detection of 19/22 (86.4%) of the RPR positive samples. With the exception of one sample all negative samples were negative by all 4 test devices. Conclusion Only a limited number of positive and negative gestational and congenital syphilis samples were evaluated in this study, due to the short supply of such rare samples. It is apparent from this limited data that by blocking the mother’s IgG an increase in sensitivity can be achieved. More in depth studies are necessary in order to prove the concept.
- 1 March 2016
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 43 (3) , 201-203
What Is the Use of Rapid Syphilis Tests in the United States?
Syphilis testing is complicated. Rapid syphilis tests may change screening practices in the United States, but first more studies are needed to demonstrate the advantages and disadvantages in the field.
- 1 March 2016
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 43 (3) , 201-203
What Is the Use of Rapid Syphilis Tests in the United States?
Syphilis testing is complicated. Rapid syphilis tests may change screening practices in the United States, but first more studies are needed to demonstrate the advantages and disadvantages in the field.
- Open Access
- 13 September 2015
- Published by BMJ in Sexually Transmitted Infections
- Vol. 91 (Suppl 2) , A29.1-A29
002.5 Evaluation of five rapid point-of-care tests for syphilis: two treponemal only, and three dual treponemal/hiv assays
Background Traditional syphilis and HIV screening strategies require laboratory capacity which is often limited in resource-poor settings. Affordable rapid point-of-care tests (RPOCT) with high sensitivity and specificity would allow same-day testing and referral for treatment of syphilis and HIV in pregnant women. This would allow a decrease in adverse outcomes as a result of mother-to-child transmission (MTCT). We compared test performance of two RPOCT treponemal tests and three combination treponemal/HIV tests for detection of treponemal antibodies in sera; and we also examined test performance of the three RPOCT treponemal/HIV tests for detection of HIV antibodies in sera. Methods We tested banked sera previously characterised for syphilis (n = 1186), from San Francisco Department of Public Health, Kaiser Permanente Northern and Southern California, and 437 known HIV-positive samples (CDC HIV), according to manufacturer’s insert with 3 dual HIV/Syphilis RPOCT: SD BIOLINE HIV Syphilis Duo (Standard Diagnostics), Multiplo TP/HIV (MedMira) and DPP HIV-syphilis Assay (Chembio), and 2 treponemal-only tests: SD Syphilis 3.0 (Standard Diagnostics), Determine SyphilisTP (Alere). Positive agreement across tests was determined and RPOCT results were compared to prior test results. Results The 5 assays had concordant positive result of 84% (1362/1623) for treponemal antibodies, and 96.6% (1569/1623) for HIV antibodies. Compared to previously reported results, treponemal tests had sensitivities and specificities of; SD 3.0 – 72%, 97.2%; SD DUO- 72.2%, 97.2%; Multiplo- 80.7%, 88.7%; Chembio – 82.5%, 96.4%; DetermineTP- 89.3%, 97.5%. The 3 treponemal/HIV assays sensitivity was100% for 437 known HIV-positives compared to standard assays. Conclusion Positive agreement was greater for HIV antibodies than for treponemal antibodies; Using banked sera could have affected performance of treponemal assays. Further prospective studies need to be performed in the field to better characterise performance of RPOCT treponemal tests. Findings from this study will provide data to guide countries’ selection of RPOCTs for syphilis and HIV screening. Disclosure of interest statement The reagents/kits for this study, were donated by the various manufacturers (Standard Diagnostics, MedMira, Chembio, and Alere).
- 13 September 2015
- Published by BMJ in Sexually Transmitted Infections
- Vol. 91 (Suppl 2) , A29.1-A29
Open Access002.5 Evaluation of five rapid point-of-care tests for syphilis: two treponemal only, and three dual treponemal/hiv assays
Background Traditional syphilis and HIV screening strategies require laboratory capacity which is often limited in resource-poor settings. Affordable rapid point-of-care tests (RPOCT) with high sensitivity and specificity would allow same-day testing and referral for treatment of syphilis and HIV in pregnant women. This would allow a decrease in adverse outcomes as a result of mother-to-child transmission (MTCT). We compared test performance of two RPOCT treponemal tests and three combination treponemal/HIV tests for detection of treponemal antibodies in sera; and we also examined test performance of the three RPOCT treponemal/HIV tests for detection of HIV antibodies in sera. Methods We tested banked sera previously characterised for syphilis (n = 1186), from San Francisco Department of Public Health, Kaiser Permanente Northern and Southern California, and 437 known HIV-positive samples (CDC HIV), according to manufacturer’s insert with 3 dual HIV/Syphilis RPOCT: SD BIOLINE HIV Syphilis Duo (Standard Diagnostics), Multiplo TP/HIV (MedMira) and DPP HIV-syphilis Assay (Chembio), and 2 treponemal-only tests: SD Syphilis 3.0 (Standard Diagnostics), Determine SyphilisTP (Alere). Positive agreement across tests was determined and RPOCT results were compared to prior test results. Results The 5 assays had concordant positive result of 84% (1362/1623) for treponemal antibodies, and 96.6% (1569/1623) for HIV antibodies. Compared to previously reported results, treponemal tests had sensitivities and specificities of; SD 3.0 – 72%, 97.2%; SD DUO- 72.2%, 97.2%; Multiplo- 80.7%, 88.7%; Chembio – 82.5%, 96.4%; DetermineTP- 89.3%, 97.5%. The 3 treponemal/HIV assays sensitivity was100% for 437 known HIV-positives compared to standard assays. Conclusion Positive agreement was greater for HIV antibodies than for treponemal antibodies; Using banked sera could have affected performance of treponemal assays. Further prospective studies need to be performed in the field to better characterise performance of RPOCT treponemal tests. Findings from this study will provide data to guide countries’ selection of RPOCTs for syphilis and HIV screening. Disclosure of interest statement The reagents/kits for this study, were donated by the various manufacturers (Standard Diagnostics, MedMira, Chembio, and Alere).